Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA: 600329)

Market Cap	20.70B
Revenue (ttm)	8.04B
Net Income (ttm)	932.37M
Shares Out	770.16M
EPS (ttm)	1.21
PE Ratio	25.46
Forward PE	20.88
Dividend	1.28 (4.16%)
Ex-Dividend Date	Jul 12, 2024

Volume	3,220,980
Open	31.41
Previous Close	31.40
Day's Range	30.75 - 31.59
52-Week Range	23.40 - 39.05
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 31, 2025

About Tianjin Pharmaceutical Da Ren Tang Group Corporation

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600329

Financial Performance

In 2023, Tianjin Pharmaceutical Da Ren Tang Group Corporation's revenue was 8.22 billion, a decrease of -0.33% compared to the previous year's 8.25 billion. Earnings were 986.71 million, an increase of 14.49%.